Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancer.
Anti-M is usually a naturally occurring cold-reactive immunoglobulin M (IgM) antibody, often with an immunoglobulin G (IgG) component, and is seldom implicated in delayed haemolytic transfusion reactions (DHTR). However, cases have been reported. In the majority, a DHTR is not suspected until further blood is requested and a new antibody is detected on pretransfusion testing. We describe the case of a young man receiving therapy with interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) for metastatic renal cell cancer who developed a clinically suspected DHTR that was confirmed serologically to be caused by anti-M, reactive at 37 degrees C. We discuss the possible role of his biochemotherapy in the development of the DHTR.
Parry-Jones
N
N
Departments of Haematology and Medicine, Royal Marsden Hospital NHS Trust, London, UK.
Gore
M E
ME
Taylor
J
J
Treleaven
J G
JG
D000328:Adult; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D001803:Blood Transfusion; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D006461:Hemolysis / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology*; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D009362:Neoplasm Metastasis; D065227:Transfusion Reaction
D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D016898:Interferon-alpha; D007376:Interleukin-2